Background {#Sec1}
==========

Cervical cancer (CxCa) is one of the most common cancers in women, with nearly 500,000 new cases being diagnosed each year worldwide \[[@CR1]\]. Its prevalence represents relevant costs for patients, their families and countries. Insiga et al. \[[@CR2]\] reported that 75% of CxCa-diagnosed women died before sixty and 25% before turning forty. Researchers also estimated that 29% of them would be professionally active in the year they died and, based on their salaries' projections, represented a revenue loss of 1.3 Billion USD, a figure superior to the direct costs associated with CxCa in the US. The introduction of cervical cytology as a screening method in the mid-twentieth century contributed to a decrease in the rate of CxCa, but its low sensitivity for CIN2+ requires a frequent repetition of the secreening process \[[@CR3]\]. As a result, there is need for more efficient and cost-effective screening methods \[[@CR4]\]. Therefore, actual knowledge lead to the definition of new strategies of prevention and practice management that include Human Papillomavirus (HPV) testing and prophylactic vaccination. Portugal started the first organized cervical cancer screening program in the Centre Region in the late 90's, extending it to more than half of the country nowadays. The HPV quadrivalent vaccine was introduced in the national vaccination program in 2008 extending the coverage to almost 90% of women. Regarding screening, the Portuguese Society of Gynaecology consensus document considers Pap Cytology with ASCUS HPV triage every three years as adequate. Nevertheless, also point out the primary high-risk HPV (hrHPV) testing with cytology triage every five years as the recommended screening algorithm \[[@CR5]\], based on the superior sensitivity of the HPV assay, validated by prospective clinical trials. Ronco G et al. (2014) \[[@CR3]\] point out that HPV-based screening provides 60--70% greater protection against invasive cervical carcinomas when compared to Pap cytology. Following this recommendation a law decret was published in 2017 confirming HPV as the primary screening test with 16/18 genotyping as a triage test for direct colposcopy and Pap cytology as a triage for other 12 hrHPV types \[[@CR6]\], which is determining a change in the screening algorithm. Despite this fact, only some of the organized screening programs implemented the project. In this context, a comparison of the clinical and budget impact of different screening strategies will help to clarify the health care gains obtained with the adoption of the new screening algorithm. This is the first budget impact analysis to date on this subject evaluating the best scenarios for Portugal.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The modelling is carried out on a hypothetical national cohort of 2,078,039 25--64-year-old Portuguese women fitting the target age groups for cervical cancer screening. The same cohort was used for all the three screening strategies under comparison \[[@CR7]\], assuming exclusion of ineligible patients, such as hysterectomized women. CxCa screening compliance rate, attendance at re-test and next routine screening were assumed to be 70.7% \[[@CR8]\] and 85.0% \[[@CR9]\], respectively.

Compared screening strategies {#Sec4}
-----------------------------

The compared screening strategies in this evaluation were based on the Portuguese Society of Gynaecology consensus on cervical cancer screening \[[@CR5]\]. Three primary CxCa screening strategies are compared. The current practice: cytology with ASCUS HPV triage every three years (Fig. [1](#Fig1){ref-type="fig"}-a). Women with normal cytology return to routine screening. Women with LSIL or worse are referred for colposcopy. ASCUS results are triaged with pooled HPV test within 6 months. HPV negative women return to routine screening and HPV-positive undergo colposcopy.Fig. 1**a** The current practice cytology with pooled HPV triage. **b** Comparator 1 pooled HPV with reflex cytology triage. **c** Comparator 2 HPV test with genotyping and reflex cytology triage

Comparator strategy 1: HPV (pooled) test with reflex cytology triage every five years (Fig. [1](#Fig1){ref-type="fig"}-b). HPV negative women return to routine screening. HPV positive results are triaged with reflex cytology. Women with cytology results ASCUS or worse are referred for colposcopy. Normal cytology results are followed up with HPV re-test in twelve months. Women with HPV-negative re-test return to routine screening and HPV-positive re-tests undergo colposcopy.

Comparator strategy 2: HPV test with 16/18 genotyping with reflex cytology triage every five years (Fig. [1](#Fig1){ref-type="fig"}-c). HPV negative women return to routine screening. Women with hrHPV genotypes 16/18 are directly referred for colposcopy. HPV genotypes other than 16/18 (HPV+ 12 types) are triaged with reflex cytology. Women with cytology results ASCUS or worse are referred to colposcopy. Normal cytology results are followed up with HPV re-test in twelve months. Women with HPV-negative re-test return to routine screening and HPV-positive re-tests undergo colposcopy.

Model structure {#Sec5}
---------------

An Excel-based (Microsoft Office 365®) budget impact model was developed to evaluate screening performance, clinical outcomes and budget impacts of the CxCa screening strategies during two routine screening cycles. The model consists of two main components: a decision-tree model and a Markov model (Fig. [2](#Fig2){ref-type="fig"}). The decision-tree simulates the performance of the screening strategies. Women are divided into three groups according to their test results; 1) healthy, who return to routine screening, 2) those who require follow-up testing, and 3) diagnosed CIN2--3 or CxCa who are treated and exit the model. The groups 1 and 2 continue to the Markov model. The Markov model simulates natural history of HPV infection, CIN and CxCa in one-month cycles. During each cycle, women can remain on the same stage, progress to the next, or regress to the previous stage. The transition probabilities between the health stages are shown in Table [1](#Tab1){ref-type="table"} \[[@CR10]--[@CR24]\]. The model does not differentiate between the stages of CxCa and only includes the probability of dying from invasive CxCa, not considering mortality from other causes.Fig. 2The model structure and patient flowTable 1Annual transition (progression / regression) probabilities of the Markov model; Natural history inputs for HPV infection, CIN, and cervical cancerModel inputReferencesAnnual ProgressioWell to hrHPV infection4.2%Kulasingam et al. (2011) \[[@CR10]\]Progression from hrHPV (12 types) to CIN18.1%Kulasingam et al. (2011) \[[@CR10]\]; Insinga RP et al. (2007) \[[@CR11]\] to CIN20.1%Khan MJ et al. (2005) \[[@CR12]\] to CIN30.1%Progression from hrHPV 16/18 to CIN19.9%Insinga RP et al. (2007) \[[@CR11]\]; Insinga RP et al. (2009) \[[@CR13]\] to CIN20.6%Khan MJ et al. (2005) \[[@CR12]\] to CIN31.5%Progression from CIN1 to CIN23.2%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; Holowaty P et al. (1999) \[[@CR15]\]; Matsumoto K et al. (2006) \[[@CR16]\]; Omori M et al. (2007) \[[@CR17]\]; Guedes AC et al. (2010) \[[@CR18]\] to CIN30.9% to CxCa0.3%Progression from CIN2 to CIN34.2%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; Holowaty P et al. (1999) \[[@CR15]\]; Matsumoto K et al. (2006) \[[@CR16]\]; Omori M et al. (2007) \[[@CR17]\]; Guedes AC et al. (2010) \[[@CR18]\] to CxCa1.8%CIN3 to CxCa3.4%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; Holowaty P et al. (1999) \[[@CR15]\]; McCredie et al. (2008) \[[@CR19]\]Annual mortality rate for CxCa0.6%SEER data. 5 year survival of 68% converted to annual mortality rate \[[@CR20]\]Annual RegressionRegression from hrHPV (12 types) with normal cytology to well58.6%Bulkmans NJ et al. (2007) \[[@CR21]\] with borderline/mild cytology to well45.6%Regression from hrHPV 16/18 with normal cytology to well43.8%Bulkmans NJ et al. (2007) \[[@CR21]\] with borderline/mild cytology to well21.8%Regression from CIN1 to well21.2%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; Holowaty P et al. (1999) \[[@CR15]\]; Matsumoto K et al. (2010) \[[@CR22]\] to hrHPV2.4%Regression from CIN2 to well9.4%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; Meyskens FL Jr. et al. (1994) \[[@CR23]\]; Holowaty P et al. (1999) \[[@CR15]\]; Matsumoto K et al. (2006) \[[@CR16]\]; Omori M et al. (2007) \[[@CR17]\]; Castle PE et al. (2009) \[[@CR24]\]; Guedes AC et al. (2010) \[[@CR18]\] to CIN19.4%Regression from CIN3 to well3.9%Weighted average: Kataja V et al. (1989) \[[@CR14]\]; McCredie et al. (2008) \[[@CR19]\] to CIN11.6%

Model inputs {#Sec6}
------------

### Epidemiology and test performance {#Sec7}

The prevalence of HPV (10.5%) and HPV genotypes 16/18 (2.1%) among 25--64-year-old women are based on the CLEOPATRE epidemiological study in Portugal \[[@CR25], [@CR26]\]. The prevalence of CIN1 (1.4%), CIN2 (0.4%), CIN3 (0.6%) and CxCa (0.048%) are taken from the ATHENA trial \[[@CR27]\]. The US-based trial assessed the performance of Thinprep® Liquid Based Cytology (Hologic) and the cobas® HPV test (Roche) in a cohort of 40,900 over 25-year-old women \[[@CR28]\] was chosen because it is one of the largest studies until now to compare the performance of Pap cytology, HPV test and partial genotyping in a screening population. Additionally, data from Portugal on this matte is unavailable. The test performance inputs of Liquid Based Cytology (LBC) and HPV test (pooled and 16/18 genotyping) are also based on the ATHENA trial data (Table [2](#Tab2){ref-type="table"}) \[[@CR28]\]. Model inputs were based on the entire cohort and not stratified by age. Data for the natural history of cervical cancer was taken from the scientific literature (Table [3](#Tab3){ref-type="table"}). Colposcopy is assumed 100% sensitive and specific.Table 2Prevalence of HPV, CIN and Cervical CancerPrevalence of hrHPV8.4%Pista et al. (2013) \[[@CR26]\]Prevalence of HPV16 and/or 182.4%Pista et al. (2013) \[[@CR26]\]Prevalence of CIN11.4%Wright et al. (2012) \[[@CR27]\]Prevalence of CIN20.4%Wright et al. (2012) \[[@CR27]\]Prevalence of CIN30.6%Wright et al. (2012) \[[@CR27]\]Prevalence of invasive cervical cancer0.048%Wright et al. (2012) \[[@CR27]\]Table 3Test performance inputs of cytology and Cobas® HPV test (pooled and 16/18 genotyping)InputValueSourceCytology (threshold ASCUS) Sensitivity CIN252.6%Castle et al. (2011) \[[@CR28]\] Sensitivity CIN352.8%Castle et al. (2011) \[[@CR28]\] Sensitivity CxCa52.8%*assumed to be equivalent to CIN3* Specificity CIN2+76.1%Castle et al. (2011) \[[@CR28]\]Cytology (threshold LSIL) Sensitivity CIN239.2%Castle et al. (2011) \[[@CR28]\] Sensitivity CIN340.1%Castle et al. (2011) \[[@CR28]\] Sensitivity CxCa40.1%*assumed to be equivalent to CIN3* Specificity CIN286.5%Castle et al. (2011) \[[@CR28]\]Cytology (threshold HSIL) Sensitivity CIN220.3%Castle et al. (2011) \[[@CR28]\] Sensitivity CIN326.2%Castle et al. (2011) \[[@CR28]\] Sensitivity CxCa26.2%*assumed to be equivalent to CIN3* Specificity CIN298.3%Castle et al. (2011) \[[@CR28]\]Cobas® HPV test (pooled) Sensitivity CIN288.2%Castle et al. (2011) \[[@CR28]\] Sensitivity CIN392.0%Castle et al. (2011) \[[@CR28]\] Sensitivity CxCa92.0%*assumed to be equivalent to CIN3* Specificity CIN257.8%Castle et al. (2011) \[[@CR28]\]Cobas® HPV test with genotyping 16/18 Sensitivity 16/18 CIN251.8%Castle et al. (2011) \[[@CR28]\] Sensitivity 16/18 CIN359.5%Castle et al. (2011) \[[@CR28]\] Sensitivity 16/18 CxCa65.3%Castle et al. (2011) \[[@CR28]\] Specificity CIN275.3%Castle et al. (2011) \[[@CR28]\]

### Costs {#Sec8}

The costs are divided into three main categories; screening, diagnostic and treatment. Cost inputs are based on the Portuguese diagnosis-related group (DRG) prices in 2014 and on published data (Table [4](#Tab4){ref-type="table"}) \[[@CR29]--[@CR31]\]. Screening costs include office visits, primary, triage and re-tests. Prices for the HPV test (pooled and 16/18 genotyping) are assumed to be the same as the DRG price of cytology (€27.40) because the current DRG price for the HPV test was set for a triage scenario and so it is too high for a primary screening test for CxCa \[[@CR29]\]. Diagnosis costs relate to diagnostic consultations, colposcopies and biopsies. Treatment costs include CIN2--3 and CxCa treatment \[[@CR30], [@CR31]\]. The budget impacts are calculated from the healthcare provider's perspective and presented in Euros.Table 4Medical costs used in the modelParameterEuroReferencesSCREENING COSTS Office visit (routine/repeat screening)31.00€\[[@CR29]\] Cytology test (liquid-based)27.40€\[[@CR29]\] HPV test (pooled)27.40€Assumed to have the same price as for cytology test HPV test with 16/18 genotyping27.40€Assumed to have the same price as for cytology testDIAGNOSTIC COSTS Office visit (diagnostic follow-up)31.00€\[[@CR29]\] Colposcopy plus biopsy34.40€\[[@CR29]\]TREATMENT COSTS Treatment for cervical intraepithelial neoplasia (Grade ≥ 2)907.57€Adapted from: Costa C \[[@CR30]\]; Santana R et al. \[[@CR31]\] Treatment for invasive cervical cancer10423.29€Adapted from: Costa C \[[@CR30]\]; Santana R et al. \[[@CR31]\]

Model outputs {#Sec9}
-------------

The performance of the screening strategies is assessed with the percentage of CIN2--3 and CxCa cases detected and with the number of colposcopies needed to detect one disease case (CIN2--3 and CxCa). The clinical impacts, in the screened population, are measured with an annual incidence of CxCa and annual CxCa mortality. The costs are presented as average annual costs during the two routine screening cycles. The annual costs are used to take into consideration the different routine screening intervals. Annual budget impacts of the primary HPV screening strategies are calculated against the current practice. Further, the costs outputs include the costs per screened woman and cost of detecting a disease (CIN2--3 and CxCa).

### Sensitivity analysis {#Sec10}

A sensitivity analysis was conducted to analyse whether clinical inputs from different published scientific literature sources \[[@CR32]--[@CR35]\], other than the primary reference used, would change the budget impact outputs of the model. A sensitivity analysis was also conducted to understand how the variation of the cost of the HPV test and LBC (half vs double) would affect the budget impact of the different screening strategies.

Results {#Sec11}
=======

Screening performance and clinical outcomes {#Sec12}
-------------------------------------------

According to the model results, the current cytology-based screening strategy detects 51.8% of CxCa and 51.9% of CIN2--3 cases. Comparator strategy 1: HPV (pooled) test with reflex cytology triage, increases the detection of CxCa to 81.0% and of CIN2--3 to 81.4%. Comparator strategy 2: HPV 16/18 genotyping with reflex cytology triage, improves the detection of CxCa to 88.6% and of CIN2--3 cases to 87.3% (Fig. [3](#Fig3){ref-type="fig"}). During the two screening cycles, the screening performances of the HPV-based comparator strategies 1 and 2 reduce annual incidence of CxCa in the screened population from 9.3 to 6.9 and 5.3 per 100,000, respectively. Furthermore, comparators 1 and 2 reduce annual CxCa mortality in the screened population from cytology-based screening from 2.7 to 1.6 and 1.1 per 100,000, respectively. This means avoiding an extra 51 CxCa deaths per year in comparator 1 and avoiding 85 extra CxCa deaths per year in comparator 2 for the simulated cohort. The number of colposcopies needed to detect a disease case (CIN2--3 and CxCa) also decrease from 10.1 to 8.2 in comparator 1 and 9.6 in comparator 2 (Table [5](#Tab5){ref-type="table"}).Fig. 3Performance of the screening strategies during two screening cycles. Detected cervical cancers and CIN2-CIN3 casesTable 5Annual cervical cancer incidence and mortality in the screened population (1,764,000 25--65-year-old Portuguese women) and per 100,000. The number of colposcopies required per detected disease (CIN2--3 and CxCa)Current practice:Comparator 1:Comparator 2:Cytology with pooled HPV triagePooled HPV test with reflex cytology triageHPV genotyping with reflex cytology triageScreened pop.per 100,000Screened pop.per 100,000Screened pop.per 100,000Annual CxCa incidence1949.31436.91095.3Annual CxCa mortality562.7341.6221.1Colposcopies per disease (CIN2--2, CxCa) detected10.18.29.6

Budget impact {#Sec13}
-------------

The average annual costs of the cytology-based strategy are €34,43 million. Annual costs of comparator 1 are €29,07 million and comparator 2 represent €29,26 million (Fig. [4](#Fig4){ref-type="fig"}). Both primary HPV screening strategies originate cost-savings. Comparator 1 decreases the total annual costs in €9,36 million (− 24%) and comparator 2 in €9,16 million (− 24%).Fig. 4Total annual costs of the screening strategies. Budget impact in comparison to the current practice. A breakdown of annual costs per screening diagnostic

Figure [4](#Fig4){ref-type="fig"} portrays a breakdown of annual costs of the three screening strategies. Screening costs are the largest component of all the three strategies. Annual screening costs (screening and triage tests and office visits) of the current practice and comparators 1 and 2 are €32,79 million, €24,41 million (− 25.6%) and €24,30 million (− 25.9%), respectively. Overall cost savings result from the reduction of screening costs. These cost savings are caused by the longer routine screening interval of the primary HPV screening strategies. Annual diagnosis costs (follow-up consultations, colposcopies and biopsies) of the current practice and comparators 1 and 2 are €1,85 million, €1,22 million (− 34.0%) and €1,53 million (− 17.0%), respectively. In both primary HPV screening strategies, the declining incidence of CIN2--3 and CxCa results in lower annual treatment costs. The treatment costs (CIN2--3 and CxCa combined) decline from €1,75 million to €1,58 million (− 9.7%) in comparator 1 and to €1,49 million (− 14.8%) in comparator 2. Average cost per screened women in the current practice and comparators 1 and 2 are €18,49, €13,99 and €14,08, respectively. In addition, the cost of detecting a disease case (CIN2--3 or CxCa) decreases from €15,845 to €13,227 in comparator 1 and to €12,795 in comparator 2.

Sensitivity analysis {#Sec14}
--------------------

The sensitivity analysis shows that the comparator screening algorithms accuracy varies in a higher level than relative costs versus the current practice. Comparator 1 (Table [6](#Tab6){ref-type="table"}) and 2 (Table [7](#Tab7){ref-type="table"}) would reduce costs vs usual care if inputs from the POBASCAM and PavDag studies would be used for modelling instead of the ATHENA \[32,33\]. Modelling with an LBC sensitivity of 73.0% for pap cytology sensitivity in this model (highest pap cytology sensitivity for CIN2+ found in the ATHENA trial) \[[@CR34]\], would improve the clinical performance of usual care, but would not alter the cost difference towards comparator strategies. On the other hand, cutting the cost of the HPV test by half (€13,7) would improve the savings vs usual care to 38.0% for comparators 1 and 2, while doubling the HPV test cost (€54,8) would still save 3.0% of the screening budget for Comparator 1 or 2.Table 6Clinical performance of triaging all hrHPV+ women with LBCStudySensitivity (CIN2+)Specificity (CIN2+)Relative cost of Comparator 1ATHENA (Castle PE et al., 2011 \[[@CR28]\])88.2%57.8%− 24%POBASCAM (Dijkstra M et al., 2013 \[[@CR32]\])66%81.4%−26%PavDag (Stanczuk GA. et al., 2017 \[[@CR33]\])68.3%89.1%− 26%Table 7Clinical performance of triaging hrHPV+ women with HPV16/18 genotyping and using LBC to triage OHRStudySensitivity (CIN2+)Specificity (CIN2+)Relative cost of Comparator 2ATHENA (Wright T et al., 2014 \[[@CR27]\])93.3%62.8%− 24%ATHENA (Castle PE et al., 2011 \[[@CR28]\])51.8%75.3%− 24%POBASCAM (Dijkstra M et al., 2013 \[[@CR32]\])90.3%57.6%−25%PavDag (Stanczuk GA. et al., 2017 \[[@CR33]\])93.3%52.7%−24%

Discussion {#Sec15}
==========

Overall, the output of the decision-tree and Markov model suggest the replacement of the current cytology-based screening with any of the two primary HPV screening strategies. It improves the detection of CIN2--3 and CxCa, displays better clinical outcomes and creates substantial cost-savings for the Portuguese healthcare system. The results are in line with similar health economic outcome research (HECON) studies \[[@CR36]--[@CR39]\] and support the current clinical consensus on the move towards molecular screening for cervical cancer not just in Portugal but also other European countries. Nevertheless, as this study is based on a computer-based model cohort, a randomized clinical trial or real-world studies with randomized samples and appropriate methodologies are needed as further research to generalize these results to the population.

The major goal of cervical cancer screening is to detect its precursor lesions and treat them before they become invasive. According to the findings of the meta-analysis of 4 European randomized trials (Swedescreen (Sweden) \[[@CR40]\], POBASCAM (Netherlands) \[[@CR41]\], ARTISTIC (England) \[[@CR42]\] and NTCC (Italy) \[[@CR43]\], reinforced by the recent findings of the COMPASS (Australia) \[[@CR44]\] and FOCAL (Canada) \[[@CR45]\]), HPV-based screening provides 60--70% greater protection against invasive cervical carcinomas compared with Pap cytology and that screening intervals may be extended to at least five years \[[@CR3]\]. In the US, the Kaiser Permanente Northern California (analysing data from more than 330,000 women) \[[@CR46]\] and the ATHENA trial (recruiting around 47,000 women) \[[@CR28]\] confirmed the vantage of the HPV test over pap cytology as a primary screening method.

In this study, HPV 16/18 genotyping with cytology triage (comparator 2) provides better clinical impacts, while lowering the costs. Therefore, it is the most cost-effective CxCa screening strategy in the Portuguese context. Comparator 2 also reduces annual CxCa incidence and mortality and reduces the total annual screening costs in 24.0%, as well as the cost of detecting a CIN2+ in 19,2%. The screening performance of HPV (pooled) test with cytology triage (comparator 1) is lower when compared to comparator 2 in its detection rates but has similar costs. The improved clinical outcomes obtained through this HECON modelling result from an improved screening performance of both HPV strategies and an earlier detection of CIN2--3 and CxCa. On the other hand, the substantial cost savings are caused by the increased length of the routine screening intervals, allowed by the enhanced sensitivity and negative predictive value of HPV based screening. The performance of Pap cytology is low in the model, but consistent with data from an international meta-analysis showing a detection rate of 53,0% \[[@CR47]\].

Concerning the triage of HPV positive women, the authors of this study acknowledge the fact that pap cytology performance as a triage marker is affected by an expected increase in sensitivity and a decrease in specificity \[[@CR48], [@CR49]\]. This means that the "real-life" sensitivity of the HPV based algorithms can be higher and specificity lower, positively impacting clinical results (CIN2+ detection) and increasing costs. To clarify this subject, a sensitivity analysis compared results from other studies that also addressed triage strategies for HPV positive women, such as POBASCAM \[[@CR32]\], PavDag \[[@CR33]\] and also from the ATHENA three years follow up results \[[@CR34]\]. The conclusion was that the cost difference towards cytology-based screening remained higher, consolidating the main findings on the cost savings created by the change towards HPV test-based screening.

The model also projects a difference in clinical outcomes between comparator 1 and 2 strategies: 5.9% in sensitivity for the detection of CxCa. The model results suggest that if the individual tests are used in a certain strategy or algorithm then the number of detected cases may differ. Although such differences were never reported from clinical trials, they can be partially explained by the fact that in this simulation, in comparator 1 all hrHPV positive / NILM cases (including HPV16 and 18 positives) are deferred and that 15.0% of these will actually miss follow-up.

This study has certain limitations. As any modelling study, the results are influenced by the input parameters and structure of the model. The performances of LBC and the HPV test (pooled and 16/18 genotyping) are based on data from a trial in the United States, not on Portuguese data. The clinical results are sensitive to changes in prevalence of HPV, HPV genotypes 16/18, CIN2 and CIN3. Also, the referral rates to colposcopy were determined in this model by the prevalence of the infection by the 14 hrHPV types in the Portuguese epidemiological study and these may differ if prevalence changes, as it is expectable in a vaccinated population. Another model limitation is that performance data reflect the baseline test (test performance among the general population) and that the same test in a re-testing situation among a previously hrHPV+ population may be different. The authors acknowledge that the model should allow two test performance inputs - one at baseline and another for re-test situation among previously hrHPV+ women. While HPV vaccination programs impact the cost of screening programs as shown in recently published real world data \[[@CR50]\], this model does not take that in consideration which may be considered also as a limitation.

The cost results are sensitive to changes in prices of cytology, HPV test and screening consultation. In the absence of a DRG reflecting the use of HPV as a screening test, the price of HPV tests was assumed the same as the cytology DRG. The future DRG price for an HPV test may be different. In this case, the authors tried to simulate the reality for Portugal as much as possible. In our country, there is no screening program at national level, and opportunistic and organized programs occur regionally with different levels of implementation. In the current setting, DRG prices are currently used as a reference for pricing both HPV and Cytology and the volume of tests would not allow for a cost reduction. A sensitive analysis varying the price of HPV test to either twice or half of that of cytology, shows that HPV based screening algorithms would remain cost-saving independently of the chosen scenario. Furthermore, the cost of screening can be lower if more suppliers compete in fair tenders. The guideline based on reproducibility and equivalent accuracy defined by Arbin et al. \[[@CR51]\] is a milestone in HPV-based cervical cancer screening. There are currently 8 HPV DNA assays fully matching these criteria, which can be recommended for HPV-based cervical cancer screening using clinician-collected cervical samples, half of which offer partial, extended or full genotyping. This means the offer is large and competitive, making public tenders able to implement either of the Comparator strategies. This is important not just for Portugal, but also for other countries. The time-horizon of this modelling study is limited to two screening cycles. Policymakers would like to understand to which level CxCa incidence and mortality decrease, after several screening cycles.

Conclusion {#Sec16}
==========

The results suggest that the replacement of the current screening practice based on cytology testing every three years to HPV primary screening with cytology triage every five years improves the detection of CIN2--3 and CxCa, provides better clinical outcomes and creates substantial cost-savings for the Portuguese healthcare system. These cost-savings are mainly generated by increasing the screening interval. Further triage of HPV positive women with partial 16/18 genotyping would improve the efficiency of the screening program. Therefore, the results of this HECON evaluation confirm the Cervical Cancer Screening recommendations of the Portuguese Society of Gynaecology \[[@CR5]\] and the ongoing screening algorithm changes in the Portuguese organized screening programs. The results of this work also open directions for future research: a) the inputs used on this model could be refined with real world data coming from the organized screening programs, b) evaluation of the economic benefit of using emerging biomarkers like p16/ki-67 or methylation to further refine the triage of HPV+ women and c) re-model taking vaccine immunization into consideration.
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